Verrica Pharmaceuticals Inc (VRCA) USD0.0001

Sell:$0.61Buy:$0.76$0.03 (4.52%)

NASDAQ:1.35%
Market closed | Prices delayed by at least 15 minutes
Sell:$0.61
Buy:$0.76
Change:$0.03 (4.52%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$0.61
Buy:$0.76
Change:$0.03 (4.52%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Key people

Jayson Rieger
President, Chief Executive Officer, Director
John J. Kirby
Interim Chief Financial Officer, Interim Principal Financial Officer
David Zawitz
Chief Operating Officer
Christopher G. Hayes
General Counsel, Company Secretary, Chief Legal Office
Gary Goldenberg
Chief Medical Officer
Paul B. Manning
Chairman of the Board
Sean Stalfort
Director
Lawrence Eichenfield
Independent Director
Diem Nguyen
Independent Director
Mark A. Prygocki
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US92511W1080
  • Market cap
    $58.06m
  • Employees
    100
  • Shares in issue
    90.67m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.